Intellia Therapeutics, Inc. (NASDAQ:NTLA) Q1 2024 Earnings Call Transcript

David Lebwohl : We were actually just meeting with investigators earlier this week and there’s excitement from these investigators for all of their patients that this can affect the disease at all stages. As you can imagine, patients with early disease, they want to prevent progression of disease. If they’re doing well for the sicker patients, they want to at least stabilize or even reverse their disease. They are really coming forward from what we are hearing from the investigators with all their patients. What we expect is about half of them have access to tafamidis, about half don’t around the world. That’s the proportions we expect in the trial. The screen failure rate is low. But we will continue that’s obviously piece of any trial that some patients might be too sick or too healthy in some cases, but it’s going very well, as you’ve heard, with more than 30 patients already randomized and more than 40 right behind them.

Operator: And our last question comes from William Pickering with Bernstein.

William Pickering : Congrats on all the progress this quarter, and thank you for taking my question. I believe you said that you filed the AATD CTA application in December. Could you share if you have received any response or feedback to that application? And once the trial is underway what duration of follow-up would you want to include in any initial data presentation?

John Leonard: David, do you want to speak to CTA status of the alpha-1 program?

David Lebwohl : With the CTA, we’ve gotten some straightforward questions that we’ve addressed. We’re expecting to hear any day back about the status of that. In terms of follow-up, we will follow the principle we always have that when we have a significant body of data to report on that we will be bringing the data forward. As a reminder, there’s Regeneron has gained approvals of both Europe and the IND cleared. So that, in terms of the application itself, the platform, we have high confidence in its ability to be go forward around the world.

Operator: At this time, I would like to turn the conference back over to Ian Karp as this concludes our question-and-answer session for any closing remarks.

Ian Karp : Thanks so much Drew, and thanks everyone for joining us today for your great questions and for your continued interest in Intellia, and we look forward to updating you as we continue to progress. Have a great day everyone.

Operator: The conference has now concluded. Thank you for your participation. You may now disconnect.